TLL018 tablets

DRUG3 trials

Sponsors

Hangzhou Highlightll Pharmaceutical Co., Ltd

Conditions

Chronic Spontaneous UrticariaModerate to Severe Plaque PsoriasisPlaque Psoriasis

Phase 1

Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis

CompletedNCT05342428

Hangzhou Highlightll Pharmaceutical Co., LtdModerate to Severe Plaque Psoriasis

Start: 2022-06-10End: 2023-08-30Updated: 2023-09-22

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

CompletedNCT05373355

Hangzhou Highlightll Pharmaceutical Co., LtdChronic Spontaneous Urticaria

Start: 2022-05-10End: 2023-09-07Updated: 2024-03-01

Phase 2

The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

CompletedNCT05772520

Hangzhou Highlightll Pharmaceutical Co., LtdPlaque Psoriasis

Start: 2023-01-19End: 2024-12-23Updated: 2026-07-21

Related Papers

Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate to severe chronic spontaneous urticaria patients with inadequate response to H1 antihistamines: a phase Ib, randomized, double-blind, placebo-controlled pilot study.

2026-03-16

Safety and efficacy of the selective tyrosine kinase 2/Janus kinase 1 inhibitor TLL-018 in moderate-to-severe plaque psoriasis: a phase Ib, randomized, double-blind, placebo-controlled study

British Journal of Dermatology2025-05-143 citations